Carboplatin + Gemcitabine + Capecitabine
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma of Unknown Primary
Conditions
Carcinoma of Unknown Primary
Trial Timeline
May 1, 2001 → Oct 1, 2007
NCT ID
NCT00148135About Carboplatin + Gemcitabine + Capecitabine
Carboplatin + Gemcitabine + Capecitabine is a phase 2 stage product being developed by Eli Lilly for Carcinoma of Unknown Primary. The current trial status is terminated. This product is registered under clinical trial identifier NCT00148135. Target conditions include Carcinoma of Unknown Primary.
What happened to similar drugs?
20 of 20 similar drugs in Carcinoma of Unknown Primary were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00148135 | Phase 2 | Terminated |
Competing Products
20 competing products in Carcinoma of Unknown Primary